When it comes to lung cancer risk, we usually think first of smoking—and with good reason. But a new study suggests that what’s on your plate might also play a surprising role. Researchers from the ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Cindy was a healthy, 35-year-old woman with no symptoms of cancer when she joined the American Lung Association’s Lung Health ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

A Rochester man celebrated being five years cancer-free Thursday by walking around Mayo Clinic thanking the doctors that saved his life.

Join us for a quick overview of BioNTech SE, a Biotechnology company whose shares moved 0.3% today. Here are some facts about ...

Immunai will generate a publicly accessible multi-omic dataset for a Parker Institute cohort of over 1,000 cancer patients.

In patients with advanced squamous non–small cell lung cancer, ivonescimab plus chemo was associated with progression-free ...

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...